Go Pro
→ The SEC Just Opened The Floodgates… (From StocksToTrade) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$8.17
+0.6%		$9.26
$6.00
▼
$11.22
$2.09B0.554.89 million shs6.14 million shs
Pharvaris N.V. stock logo
PHVS
Pharvaris
$31.19
+0.6%		$35.11
$20.65
▼
$43.25
$2.04B-2.46425,303 shs591,358 shs
Vericel Corporation stock logo
VCEL
Vericel
$40.15
+1.8%		$42.14
$28.95
▼
$49.32
$2.06B1.02579,379 shs480,322 shs
YD Bio Limited stock logo
YDES
YD Bio
$8.11
+3.8%		$3.74
$1.70
▼
$22.00
$574.11M-1.6145,289 shs546,509 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
-2.52%-4.69%-18.15%-17.48%+10.18%
Pharvaris N.V. stock logo
PHVS
Pharvaris
-2.24%-6.00%-11.22%-8.42%+28.89%
Vericel Corporation stock logo
VCEL
Vericel
-1.74%+0.36%-2.62%-16.05%+27.60%
YD Bio Limited stock logo
YDES
YD Bio
+5.26%+63.73%+106.61%+311.05%+780,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$8.17
+0.6%		$9.26
$6.00
▼
$11.22
$2.09B0.554.89 million shs6.14 million shs
Pharvaris N.V. stock logo
PHVS
Pharvaris
$31.19
+0.6%		$35.11
$20.65
▼
$43.25
$2.04B-2.46425,303 shs591,358 shs
Vericel Corporation stock logo
VCEL
Vericel
$40.15
+1.8%		$42.14
$28.95
▼
$49.32
$2.06B1.02579,379 shs480,322 shs
YD Bio Limited stock logo
YDES
YD Bio
$8.11
+3.8%		$3.74
$1.70
▼
$22.00
$574.11M-1.6145,289 shs546,509 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
-2.52%-4.69%-18.15%-17.48%+10.18%
Pharvaris N.V. stock logo
PHVS
Pharvaris
-2.24%-6.00%-11.22%-8.42%+28.89%
Vericel Corporation stock logo
VCEL
Vericel
-1.74%+0.36%-2.62%-16.05%+27.60%
YD Bio Limited stock logo
YDES
YD Bio
+5.26%+63.73%+106.61%+311.05%+780,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
2.50
Moderate Buy$20.50150.92% Upside
Pharvaris N.V. stock logo
PHVS
Pharvaris
2.80
Moderate Buy$59.8791.94% Upside
Vericel Corporation stock logo
VCEL
Vericel
2.67
Moderate Buy$58.4045.45% Upside
YD Bio Limited stock logo
YDES
YD Bio
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest YDES, BCRX, VCEL, and PHVS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/30/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$12.00 ➝ $13.00
9/22/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C) ➝ Sell (D-)
9/14/2026
Pharvaris N.V. stock logo
PHVS
Pharvaris
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$65.00
9/10/2026
Pharvaris N.V. stock logo
PHVS
Pharvaris
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$40.00 ➝ $44.00
9/10/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform ➝ Sector Perform$13.00 ➝ $11.00
9/9/2026
Pharvaris N.V. stock logo
PHVS
Pharvaris
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$42.00 ➝ $50.00
9/9/2026
Pharvaris N.V. stock logo
PHVS
Pharvaris
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$50.00 ➝ $65.00
9/9/2026
Pharvaris N.V. stock logo
PHVS
Pharvaris
Rosenblatt Securities logo
Rosenblatt Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$60.00
9/9/2026
Pharvaris N.V. stock logo
PHVS
Pharvaris
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$46.00 ➝ $62.00
9/9/2026
Pharvaris N.V. stock logo
PHVS
Pharvaris
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$79.00
9/9/2026
Pharvaris N.V. stock logo
PHVS
Pharvaris
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$55.00 ➝ $65.00
(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$874.84M2.39$1.21 per share6.73($0.57) per share-14.33
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/AN/AN/AN/A$4.71 per shareN/A
Vericel Corporation stock logo
VCEL
Vericel
$276.26M7.44$0.56 per share72.26$7.01 per share5.73
YD Bio Limited stock logo
YDES
YD Bio
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$263.86M-$1.50N/A11.35N/A-40.90%-86.89%66.37%11/2/2026 (Estimated)
Pharvaris N.V. stock logo
PHVS
Pharvaris
-$198.79M-$3.05N/AN/AN/AN/A-61.40%-56.00%11/11/2026 (Estimated)
Vericel Corporation stock logo
VCEL
Vericel
$16.52M$0.4785.4347.80N/A7.91%6.91%5.02%11/5/2026 (Estimated)
YD Bio Limited stock logo
YDES
YD Bio
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest YDES, BCRX, VCEL, and PHVS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/1/2026Q2 2026
YD Bio Limited stock logo
YDES
YD Bio
N/A$0.05N/A$0.0450N/A$0.42 million
8/12/2026Q2 2026
Pharvaris N.V. stock logo
PHVS
Pharvaris
-$0.7467-$0.81-$0.0633-$0.80N/AN/A
8/5/2026Q2 2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$0.1542$0.30+$0.1458$0.30$183.28 million$218.25 million
7/30/2026Q2 2026
Vericel Corporation stock logo
VCEL
Vericel
-$0.0289$0.04+$0.0689$0.04$72.70 million$77.46 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/AN/AN/AN/AN/A
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/AN/AN/AN/AN/A
Vericel Corporation stock logo
VCEL
Vericel
N/AN/AN/AN/AN/A
YD Bio Limited stock logo
YDES
YD Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/A
2.32
2.29
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/A
11.94
11.94
Vericel Corporation stock logo
VCEL
Vericel
N/A
5.04
4.69
YD Bio Limited stock logo
YDES
YD Bio
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
85.88%
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/A
Vericel Corporation stock logo
VCEL
Vericel
N/A
YD Bio Limited stock logo
YDES
YD Bio
N/A

Insider Ownership

CompanyInsider Ownership
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
3.80%
Pharvaris N.V. stock logo
PHVS
Pharvaris
11.84%
Vericel Corporation stock logo
VCEL
Vericel
7.60%
YD Bio Limited stock logo
YDES
YD Bio
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
435255.54 million245.83 millionOptionable
Pharvaris N.V. stock logo
PHVS
Pharvaris
14865.41 million57.66 millionNot Optionable
Vericel Corporation stock logo
VCEL
Vericel
39851.21 million47.32 millionOptionable
YD Bio Limited stock logo
YDES
YD Bio
1570.79 millionN/AN/A

Recent News About These Companies

Wall Street Zen Upgrades YD Bio (NASDAQ:YDES) to "Hold"
September 26, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31051451
Cours YD Bio Limited
September 24, 2026  |  zonebourse.comZ
YD Bio (NASDAQ:YDES) CEO Ethan Phd Shen Purchases 3,100 Shares of Stock
September 11, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-ydes-insider-buying-and-selling-2026-09-11/
中概股跌幅榜前十，YD Bio Limited(YDES.US)跌22.71%，房多多(DUO.US)跌20.85%
September 1, 2026  |  finet.hkF
YD Bio Ltd (YDES)
September 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/YDES/news/
YD Bio Files First-Half 2026 Results, Reports Improved Equity Position
September 1, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/yd-bio-files-first-half-2026-results-reports-improved-equity-position?utm_source=marketbeat.com&utm_medium=referral
YD Bio Limited Reports First-Half 2026 Financial Results, 315% Revenue Growth and Net Income of $6.7 Million
August 31, 2026  |  quiverquant.comQ
YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026
August 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/31/3353740/0/en/yd-bio-limited-reports-unaudited-financial-results-for-the-six-months-ended-june-30-2026.html
YDES - YD Bio Limited
August 26, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/YDES/historical-price-quotes
Yd Bio Limited publie un article de revue évalué par les pairs dans Nutrients et lance deux produits nutraceutiques à Taïwan
August 26, 2026  |  zonebourse.comZ
YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
August 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/25/3350403/0/en/yd-bio-announces-peer-reviewed-publication-in-nutrients-co-authored-with-physicians-from-the-taiwan-chronic-disease-healthcare-association-and-the-future-health-institute.html
YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare ...
August 11, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/yd-bio-launches-a-physician-partnership-initiative-in-taiwan-with-the-announcement-of-two-nutraceutical-products-in-collaboration-with-the-taiwan-chronic-disease-healthcare-association-and-the-1036440665
YD Bio Launches Physician-Led Nutraceuticals in Taiwan to Build Consumer Health Ecosystem
August 11, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/yd-bio-launches-physician-led-nutraceuticals-in-taiwan-to-build-consumer-health-ecosystem?utm_source=marketbeat.com&utm_medium=referral
YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research
August 4, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/yd-bio-highlights-peer-reviewed-publication-on-new-computational-framework-for-keratoconus-research-1036405738
YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada
July 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/yd-bio-launches-cross-border-120000068.html
YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services
July 24, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/yd-bio-and-eg-biomed-conclude-successful-exhibition-at-bio-asia-taiwan-2026-highlighting-innovations-in-ophthalmology-oncology-diagnostics-and-clinical-services-1036356738
YD Bio Limited
July 15, 2026  |  cnn.comhttps://www.cnn.com/markets/stocks/YDES
YD Bio Limited Ordinary Shares (YDES) Insider Activity
July 14, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/ydes/insider-activity
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
July 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/02/3321265/0/en/yd-bio-expands-u-s-laboratory-footprint-to-46-states-strengthening-dna-methylation-early-cancer-detection-operations.html
YD Bio Ltd.
June 25, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/ydes/research-ratings

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioCryst Pharmaceuticals stock logo

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.17 +0.05 (+0.62%)
Closing price 04:00 PM Eastern
Extended Trading
$8.09 -0.08 (-0.98%)
As of 04:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Pharvaris stock logo

Pharvaris NASDAQ:PHVS

$31.19 +0.18 (+0.58%)
Closing price 04:00 PM Eastern
Extended Trading
$31.17 -0.02 (-0.06%)
As of 04:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Vericel stock logo

Vericel NASDAQ:VCEL

$40.15 +0.71 (+1.80%)
Closing price 04:00 PM Eastern
Extended Trading
$40.16 +0.01 (+0.02%)
As of 04:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

YD Bio stock logo

YD Bio NASDAQ:YDES

$8.11 +0.30 (+3.84%)
Closing price 04:00 PM Eastern
Extended Trading
$7.78 -0.33 (-4.12%)
As of 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas